• 31455 Citations
  • 75 h-Index
1982 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Yung Jue Bang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 44 Similar Profiles
Stomach Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
Stomach Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1982 2019

Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer

Park, H., Bang, J. H., Nam, A. R., Eun Park, J., Hua Jin, M., Bang, Y. J. & Oh, D-Y., 1 Dec 2019, In : Scientific Reports. 9, 1, 11131.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
Pancreatic Neoplasms
Ligands
Drug Therapy
Disease Progression
Tumor Microenvironment

Jab1 silencing inhibits proliferation and sensitizes to cisplatin in biliary tract cancer

Nam, A. R., Kim, J. W., Park, J. E., Bang, J. H., Jin, M. H., Oh, D-Y. & Bang, Y. J., 1 Jul 2019, In : Cancer Research and Treatment. 51, 3, p. 886-900 15 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
Biliary Tract Neoplasms
Cisplatin
Small Interfering RNA
G1 Phase Cell Cycle Checkpoints
DNA Damage

Therapeutic targeting of the DNA damage response using an ATR inhibitor in biliary tract cancer

Nam, A. R., Jin, M. H., Park, J. E., Bang, J. H., Oh, D-Y. & Bang, Y. J., 1 Jul 2019, In : Cancer Research and Treatment. 51, 3, p. 1167-1179 13 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
Biliary Tract Neoplasms
Ataxia Telangiectasia
DNA Damage
Cytotoxins
Comet Assay
Clinical Trials, Phase I
Korea
Clinical Trials
Pharmaceutical Preparations
Translational Medical Research
3 Citations (Scopus)

Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors

Jung, K. H., LoRusso, P., Burris, H., Gordon, M., Bang, Y. J., Hellmann, M. D., Cervantes, A., Ochoa de Olza, M., Marabelle, A., Stephen Hodi, F., Ahn, M. J., Emens, L. A., Barlesi, F., Hamid, O., Calvo, E., McDermott, D., Soliman, H., Rhee, I., Lin, R., Pourmohamad, T. & 7 others, Suchomel, J., Tsuhako, A., Morrissey, K., Mahrus, S., Morley, R., Pirzkall, A. & Lindsey Davis, S., 1 Jun 2019, In : Clinical Cancer Research. 25, 11, p. 3220-3228 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Indoleamine-Pyrrole 2,3,-Dioxygenase
Pharmacokinetics
Kynurenine
Neoplasms
Triple Negative Breast Neoplasms